YBX3 and cancer: However, significant correlations were observed between overexpressed YBX3 and the cancer stage (stage III and IV vs. stage I and II; P < 0.001), T stage (T3 and 4 vs. T1 and 2; P < 0.001), sex (female vs. male; P < 0.001), primary therapy outcome [progressive disease (PD) and stable disease (SD) and partial response (PR) vs. complete response (CR); P < 0.05], hemoglobin (elevated vs. low and normal; P < 0.05), and OS [progression free interval (PFI) and disease specific survival (DSS) events (alive vs. dead); P < 0.001] (Table 2).